RICHARD JUMBA: Open Payments
NPI 1245941301 · RANCHO CUCAMONGA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,424 in 215 payments from 16 companies in 2025. Trend: 2023 $1,548 · 2024 $3,868 · 2025 $4,424
Food & beverage: $4,424
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $597 |
| Alkermes, Inc. | 25 | $597 |
| Otsuka America Pharmaceutical, Inc. | 28 | $567 |
| Neurocrine BioSciences, Inc. | 20 | $431 |
| Axsome Therapeutics, Inc. | 15 | $330 |
| Janssen Pharmaceuticals, Inc | 12 | $295 |
| Teva Pharmaceuticals USA, Inc. | 13 | $278 |
| Lundbeck LLC | 17 | $263 |
| Vanda Pharmaceuticals Inc. | 12 | $250 |
| ABBVIE INC. | 16 | $237 |
Products named: CAPLYTA, ARISTADA, REXULTI, INGREZZA, Auvelity, ABILIFY ASIMTUFII, VRAYLAR, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
